Matrix metalloproteinases and angiogenic factors: predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer?
about
Finasteride inhibits human prostate cancer cell invasion through MMP2 and MMP9 downregulation.Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastasesSteps in prostate cancer progression that lead to bone metastasisMatrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets.Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression.Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer.Plumbagin, a medicinal plant (Plumbago zeylanica)-derived 1,4-naphthoquinone, inhibits growth and metastasis of human prostate cancer PC-3M-luciferase cells in an orthotopic xenograft mouse model.Clinical Significance of Wnt/β-Catenin Signalling and Androgen Receptor Expression in Prostate Cancer.Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?Immunohistochemical expression of matrix metalloproteinase-9 and inhibitor of matrix metalloproteinase-1 in prostate adenocarcinoma.Downregulated expression of hepatoma-derived growth factor inhibits migration and invasion of prostate cancer cells by suppressing epithelial-mesenchymal transition and MMP2, MMP9.Elevation of SHARPIN Protein Levels in Prostate Adenocarcinomas Promotes Metastasis and Impairs Patient Survivals.
P2860
Q35081036-8B934634-647F-4190-9151-38A9C78C4E02Q35185360-52F133EF-4441-4A83-90A3-253B6862FD08Q37848782-55E4F0B1-E9F6-4FCF-90C4-DC67D8B7A8D3Q38107451-2EBD6C7B-6002-4BC0-BBE5-5CD586390759Q38224605-95130918-6831-4E87-9AF2-F726AFD5CCA4Q38739235-B656D8C1-DF07-42D3-9911-0B67A63907BDQ39209834-6677FDF7-D1DE-4723-A77A-0351E26379A2Q39219294-D8DADDC0-AA76-4D74-9622-81F450A500F9Q40246462-38052EF5-DCCF-4524-9246-B6E956691CF3Q41548112-66C688A0-ADD9-4C8D-AE43-B29B53AF524BQ41813299-DF54B69F-A3C5-4619-ACB6-79A46EC260FFQ47210101-5462ED9A-8722-4F6A-BD36-3F16B7CB6933Q51125940-E6ABB96D-D0E1-4110-9230-3B2934FD3BE2
P2860
Matrix metalloproteinases and angiogenic factors: predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer?
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Matrix metalloproteinases and ...... rgan-confined prostate cancer?
@ast
Matrix metalloproteinases and ...... rgan-confined prostate cancer?
@en
Matrix metalloproteinases and ...... rgan-confined prostate cancer?
@nl
type
label
Matrix metalloproteinases and ...... rgan-confined prostate cancer?
@ast
Matrix metalloproteinases and ...... rgan-confined prostate cancer?
@en
Matrix metalloproteinases and ...... rgan-confined prostate cancer?
@nl
prefLabel
Matrix metalloproteinases and ...... rgan-confined prostate cancer?
@ast
Matrix metalloproteinases and ...... rgan-confined prostate cancer?
@en
Matrix metalloproteinases and ...... rgan-confined prostate cancer?
@nl
P2093
P2860
P1476
Matrix metalloproteinases and ...... rgan-confined prostate cancer?
@en
P2093
George N Thalmann
Lucas M Bachmann
Regula Markwalder
Silvan Boxler
Thomas M Kessler
Valentin Djonov
P2860
P304
P356
10.2353/AJPATH.2010.091190
P407
P577
2010-10-01T00:00:00Z